Global Venous Stents Market Size Likely to Expand at a CAGR of 11.40% By 2034

Global Venous Stents Market size was valued at USD 1,440.6 Million in 2025 and is projected to reach USD 2,987.7 Million by 2034, growing at a CAGR of 11.40% from 2024 to 2034 during the forecast period 2025 – 2034.

Venous Stents Market: Growth Factors and Dynamics

What is the reason for the increasing significance of venous stents in managing vascular diseases?

Venous stents have become an essential management tool for chronic venous diseases, providing a minimally invasive solution for patients with venous obstructions, deep vein thrombosis (DVT), and other vascular conditions. However, what is the reason for the critical role of these devices in contemporary vascular care? Venous stents are small, metal tubes that resemble mesh and are inserted into veins to prevent vein collapse or blockage and restore correct blood flow.

They are specifically engineered to address venous insufficiencies, a condition in which the veins cannot effectively return blood from the lower extremities back to the heart, resulting in symptoms such as varicose veins, edema, and pain.

In contrast to arterial stents, which are employed in arteries that regulate high-pressure blood flow, venous stents are designed to be more effective in veins with reduced blood pressure and distinct structural characteristics. Due to their design, they are highly effective in maintaining vein patency and alleviating symptoms associated with venous obstruction, which guarantees conformity and flexibility to the vessel wall.

The growing prevalence of chronic venous disorders, which affect millions of individuals worldwide and can result in severe complications if left untreated, is the primary factor driving the demand for venous stents. Stenting is the preferable therapeutic option due to the fact that traditional treatment options, such as anticoagulant medication and compression therapy, frequently fail to manage advanced cases of venous obstruction effectively.

Venous stents provide a permanent solution by physically opening narrowed or obstructed veins, thereby enhancing blood flow and reducing the likelihood of complications such as recurrent thrombosis and leg ulcers. In the treatment of conditions such as post-thrombotic syndrome (PTS) and iliac vein compression syndrome (May-Thurner syndrome), the adoption of venous stents is particularly prevalent.

Stenting has been demonstrated to enhance patient outcomes and quality of life substantially. Healthcare providers are progressively selecting venous stents as the initial treatment for complex venous pathologies as awareness of venous diseases and the advantages of stenting continue to expand.

What are the market trends that are influencing the adoption of venous stents in vascular treatment?

In vascular treatment, the adoption of venous stents is influenced by various emerging market trends, which are indicative of the changing requirements of patients and healthcare providers. The growing emphasis on minimally invasive procedures is one of the most notable trends.

There has been a significant shift toward endovascular treatments for venous diseases as patients and clinicians prioritize shorter hospital stays, lower complication rates, and quicker recovery times. Venous stenting is a preferred choice for the management of chronic venous insufficiency and venous obstructions due to its minimally invasive nature, which provides a less traumatic alternative to traditional open surgery.

This trend is particularly apparent in developed regions, where the extensive adoption of minimally invasive techniques is facilitated by high patient awareness levels and advanced healthcare infrastructure. The transition to outpatient procedures has also driven the demand for venous stents, as these devices can frequently be implanted in a same-day setting, thereby mitigating the disruption to patients’ daily lives.

Report Scope

Venous Stents Market: Significant Developments

• After a recall in May 2021, Becton Dickinson (BD) reintroduced its Venovo venous stent to the U.S. market in May 2022. The Venovo stent, which was initially approved by the FDA, was specifically designed to address iliofemoral vein obstruction.

• Bentley Innomed Gmbh acquired Qmedics in April 2024 to broaden its portfolio of self-expanding stents for peripheral endovascular procedures, including interventional radiology.

List of the prominent players in the Venous Stents Market:

• Abbott Laboratories
• Becton Dickinson and Company
• Bentley
• Boston Scientific Corporation
• Cardinal Health
• Cook Group Incorporated
• Koninklijke Philips N.V.
• Medtronic
• Shanghai MicroPort Endovascular MedTech(Group)Co. Ltd.
• W. L. Gore & Associates Inc.
• Others

The Venous Stents Market is segmented as follows:

By Technology

• Iliac Vein Stent Technology
• Wallstent Technology

By Disease

• Acute DVT
• Chronic DVT/PTS
• NIVL/MTS
• Others

By Application

• Leg
• Chest
• Abdomen
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America